Project Grant R21NS136877
- The National Institutes of Health's Office of the Director awarded a $8,661,331 project grant under the Lung Diseases Research program (CFDA 93.838) to the Massachusetts General Hospital on June 10, 2021 for the development of interactive data portals and analytic tools to support Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) cohorts. Key products and services delivered through Massachusetts General Hospital and several sub-awardees include an interactive data portal called the...
- Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $1,375,619 to the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center on August 1, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate pulmonary neuroimmune determinants of immunoglobulin production against pneumonia through April 30, 2030. This Project Grant funds research examining how sensory neurons regulate B cell maturation, immunoglobulin production, and class...
- Federal Project Grant Award Summary The University of Pennsylvania received a $175,428 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, through July 31, 2027. This grant funds research to investigate virus-specific T cell activation mechanisms in Long COVID (LC) patients, with the objective of identifying underlying disease pathology and potential therapeutic...
- Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $582,172 to Louisiana State University Health Sciences Center-Shreveport on May 13, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The research project, which will be completed by April 30, 2030, investigates the mechanistic relationship between viral infection and the progression of Lewy pathology and dementia. The award funds a...
- GRANT AWARD SUMMARY New York University School of Medicine received a $712,578 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective February 1, 2026, through December 31, 2030. The award funds a prospective epidemiological study designed to investigate the association between viral infections and subsequent risk of Alzheimer's disease (AD) using three prospective cohorts. The research employs VirScan, a bacteriophage...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded the University of Illinois a $2.55 million Project Grant under the Aging Research program (CFDA 93.866) on August 11, 2025, with a completion date of July 31, 2029. This research project investigates the mechanisms by which SARS-CoV-2 infection increases the risk of vascular contributions to cognitive impairment and dementia (VCID). The research will examine how COVID-19 weakens the blood-brain barrier (BBB) through...
- This $131,988 Project Grant from the National Heart, Lung and Blood Institute, part of the Department of Health and Human Services, supports research targeting determinants of SARS-CoV-2 host interaction in airways. Funded through the Cardiovascular Diseases Research program, the grant aims to identify master regulator proteins that mechanistically regulate SARS-CoV-2 interactions in the airways. Using organotypic airway epithelial culture and systems biology tools at Columbia University, the...
- The National Institute on Aging awarded a $1,931,965 Project Grant (CFDA 93.866 - Aging Research) to the Regenerative Research Foundation, a non-profit organization in Albany, New York. The purpose of this federal grant is to develop and validate a novel human induced pluripotent stem cell (iPSC) model that incorporates cerebral cortical neurons, glia, vascular endothelial cells, and microglia to study cerebrovascular interactions in Alzheimer's disease-related dementias (ADRD). The R61 phase of...
- This $693,942 National Institutes of Health National Heart Lung and Blood Institute Project Grant funds research at Northwestern University aimed at elucidating epigenetic modifiers of regulatory T cell function following viral pneumonia. The goal is to establish causal links between DNA methyltransferase activity, the DNMT adapter UHRF1, and DNA hypermethylation signatures in regulatory T cells during aging and their impaired reparative function after severe viral pneumonia. Through three...
- Federal Project Grant Summary The Regenerative Research Foundation received a $428,175 Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866) effective February 15, 2026, through February 14, 2028. The award funds development of a human induced pluripotent stem cell (iPSC)-derived microphysiological 3D vascular model to investigate Alzheimer's disease-related vascular pathology, specifically cerebral amyloid angiopathy (CAA). The deliverables...
LEVERAGING IPSC TECHNOLOGY TO UNDERSTAND NEURO-IMMUNE RESPONSES TO SARS-COV-2 VARIANTS - PROJECT SUMMARY THE COVID-19 PANDEMIC HAS LED TO SIGNIFICANT MORBIDITY AND MORTALITY GLOBALLY. WHILE VACCINATION HAS DRAMATICALLY REDUCED INCIDENCE OF SEVERE COVID-19 CASES, SARS-COV-2 CONTINUES TO CIRCULATE WITH NEW VARIANTS ARISING. IMPORTANTLY, EVEN MILD COVID-19 CAN LEAD TO LONG TERM CONSEQUENCES TERMED POST-ACUTE SEQUELAE OF SARS-COV-2 INFECTION (PASC) OR "LONG COVID". THE CURRENT PROPOSAL WILL USE INNOVATIVE STEM CELL TECHNOLOGY TO STUDY MECHANISMS UNDERLYING NEUROLOGICAL AND PSYCHIATRIC SYMPTOMS OF PASC. NEUROINFLAMMATION, INCLUDING MICROGLIAL ACTIVATION, IS A HALLMARK OF PASC AND CELL LINE MODELS HAVE DEMONSTRATED THAT SARS-COV-2 OR SARS- COV-2 PROTEINS CAN INDUCE PRO-INFLAMMATORY RESPONSES IN MICROGLIA. WHAT REMAINS UNKNOWN, HOWEVER, ARE THE SPECIFIC CELLULAR AND MOLECULAR MECHANISMS BY WHICH SARS-COV-2 AFFECTS MICROGLIAL-NEURONAL CROSSTALK. HERE, WE WILL GENERATE MICROGLIA AND 3D BRAIN ORGANOIDS FROM HUMAN INDUCED PLURIPOTENT STEM CELLS (IPSC) WHICH ARE CLINICALLY RELEVANT MODELS TO STUDY NEUROIMMUNE INTERACTIONS. OUR PRELIMINARY DATA INDICATE THAT SARS-COV-2 CAN ENTER BUT NOT EFFICIENTLY REPLICATE IN HUMAN MICROGLIA. WE DID, HOWEVER, OBSERVE SIGNIFICANT TRANSCRIPTIONAL REMODELING FOLLOWING SARS-COV-2 EXPOSURE INVOLVING INFLAMMATORY, ANTIVIRAL, AND METABOLIC PATHWAYS. INTERESTINGLY, THESE RESPONSES WERE STRAIN-SPECIFIC WITH THE STRONGEST CHANGES OBSERVED AFTER SARS-COV-2 WASHINGTON (ROOT-LINEAGE STRAIN) STIMULATION AND MORE MODERATE RESPONSES TO DELTA AND OMICRON VARIANTS. IN THE CURRENT PROJECT, WE AIM TO FURTHER ELUCIDATE MOLECULAR MECHANISM OF PASC-RELATED NEUROINFLAMMATION. SPECIFICALLY, WE WILL PERFORM MULTI-OMIC AND FUNCTIONAL CHARACTERIZATION OF SARS-COV-2 INFECTED MICROGLIA AND CROSS-REFERENCE THESE SIGNATURES WITH MOLECULAR MARKERS OBSERVED IN PASC (AIM 1). WE WILL FURTHER GENERATE MICROGLIA-INCORPORATED BRAIN ORGANOIDS AND STUDY THE IMPACT OF SARS-COV-2 ON MICROGLIA-NEURONAL COMMUNICATION AS WELL AS NEURONAL ACTIVITY (AIM 2). TAKEN TOGETHER, THE PROPOSED EXPERIMENTS WILL PROVIDE AN IMPORTANT PROOF OF PRINCIPLE FOR THE USE OF STEM CELL TECHNOLOGY TO REVEAL MOLECULAR CHARACTERISTICS OF MICROGLIAL RESPONSES TO SARS-COV-2 AND VARIANTS, SHEDDING NEW LIGHT ON PATHOGENIC MECHANISMS UNDERLYING NEURO-PASC AND PROVIDING A PLATFORM FOR FUTURE DRUG DEVELOPMENT.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $195.6k | 3/24/25 | ||
| Not listed | $234.8k | 4/10/24 | ||
| Not listed | $234.8k | 4/10/24 |